These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 12873147)

  • 21. The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic.
    Tsantrizos YS
    Biopolymers; 2004; 76(4):309-23. PubMed ID: 15386268
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanistic role of NS4A and substrate in the activation of HCV NS3 protease.
    Zhu H; Briggs JM
    Proteins; 2011 Aug; 79(8):2428-43. PubMed ID: 21633972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Competitive inhibition of the dengue virus NS3 serine protease by synthetic peptides representing polyprotein cleavage sites.
    Chanprapaph S; Saparpakorn P; Sangma C; Niyomrattanakit P; Hannongbua S; Angsuthanasombat C; Katzenmeier G
    Biochem Biophys Res Commun; 2005 May; 330(4):1237-46. PubMed ID: 15823576
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reactivity at the substrate activation site of yeast pyruvate decarboxylase: inhibition by distortion of domain interactions.
    Baburina I; Dikdan G; Guo F; Tous GI; Root B; Jordan F
    Biochemistry; 1998 Feb; 37(5):1245-55. PubMed ID: 9477950
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potent 7-hydroxy-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid-based macrocyclic inhibitors of hepatitis C virus NS3 protease.
    Chen KX; Njoroge FG; Pichardo J; Prongay A; Butkiewicz N; Yao N; Madison V; Girijavallabhan V
    J Med Chem; 2006 Jan; 49(2):567-74. PubMed ID: 16420042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis C virus NS3 protease is activated by low concentrations of protease inhibitors.
    Dahl G; Arenas OG; Danielson UH
    Biochemistry; 2009 Dec; 48(48):11592-602. PubMed ID: 19839643
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel hepatitis C virus protease inhibitors: thiazolidine derivatives.
    Sudo K; Matsumoto Y; Matsushima M; Fujiwara M; Konno K; Shimotohno K; Shigeta S; Yokota T
    Biochem Biophys Res Commun; 1997 Sep; 238(2):643-7. PubMed ID: 9299567
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel azapeptide inhibitors of hepatitis C virus serine protease.
    Bailey MD; Halmos T; Goudreau N; Lescop E; Llinàs-Brunet M
    J Med Chem; 2004 Jul; 47(15):3788-99. PubMed ID: 15239657
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Flavins inhibit human cytomegalovirus UL80 protease via disulfide bond formation.
    Baum EZ; Ding WD; Siegel MM; Hulmes J; Bebernitz GA; Sridharan L; Tabei K; Krishnamurthy G; Carofiglio T; Groves JT; Bloom JD; DiGrandi M; Bradley M; Ellestad G; Seddon AP; Gluzman Y
    Biochemistry; 1996 May; 35(18):5847-55. PubMed ID: 8639546
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thermodynamics of zinc binding to hepatitis C virus NS3 protease: a folding by binding event.
    Abian O; Neira JL; Velazquez-Campoy A
    Proteins; 2009 Nov; 77(3):624-36. PubMed ID: 19536779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Viral NS3 helicase activity is inhibited by peptides reproducing the Arg-rich conserved motif of the enzyme (motif VI).
    Borowski P; Heising MV; Miranda IB; Liao CL; Choe J; Baier A
    Biochem Pharmacol; 2008 Jul; 76(1):28-38. PubMed ID: 18479669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design.
    Venkatraman S; Njoroge FG; Girijavallabhan VM; Madison VS; Yao NH; Prongay AJ; Butkiewicz N; Pichardo J
    J Med Chem; 2005 Aug; 48(16):5088-91. PubMed ID: 16078825
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Screening and rank ordering of reversible mechanism-based inhibitors of hepatitis C virus NS3 protease using electrospray ionization mass spectrometry.
    Liu YH; Ramanathan L; Malcolm B; Njoroge G; Chan TY; Pramanik BN
    J Mass Spectrom; 2011 Aug; 46(8):764-71. PubMed ID: 21766396
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A systematic approach to the optimization of substrate-based inhibitors of the hepatitis C virus NS3 protease: discovery of potent and specific tripeptide inhibitors.
    Llinàs-Brunet M; Bailey MD; Ghiro E; Gorys V; Halmos T; Poirier M; Rancourt J; Goudreau N
    J Med Chem; 2004 Dec; 47(26):6584-94. PubMed ID: 15588093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Use of the fused NS4A peptide-NS3 protease domain to study the importance of the helicase domain for protease inhibitor binding to hepatitis C virus NS3-NS4A.
    Thibeault D; Massariol MJ; Zhao S; Welchner E; Goudreau N; Gingras R; Llinàs-Brunet M; White PW
    Biochemistry; 2009 Feb; 48(4):744-53. PubMed ID: 19119853
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of prime-site occupancy on the hepatitis C virus NS3 protease structure.
    Casbarra A; Piaz FD; Ingallinella P; Orrù S; Pucci P; Pessi A; Bianchi E
    Protein Sci; 2002 Sep; 11(9):2102-12. PubMed ID: 12192066
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Peptidomimetic therapeutic agents targeting the protease enzyme of the human immunodeficiency virus and hepatitis C virus.
    Tsantrizos YS
    Acc Chem Res; 2008 Oct; 41(10):1252-63. PubMed ID: 18681464
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery and characterization of a substrate selective p38alpha inhibitor.
    Davidson W; Frego L; Peet GW; Kroe RR; Labadia ME; Lukas SM; Snow RJ; Jakes S; Grygon CA; Pargellis C; Werneburg BG
    Biochemistry; 2004 Sep; 43(37):11658-71. PubMed ID: 15362850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potent aza-peptide derived inhibitors of HCV NS3 protease.
    Venkatraman S; Wu W; Shih NY; George Njoroge F
    Bioorg Med Chem Lett; 2009 Aug; 19(16):4760-3. PubMed ID: 19596195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations.
    Courcambeck J; Bouzidi M; Perbost R; Jouirou B; Amrani N; Cacoub P; Pèpe G; Sabatier JM; Halfon P
    Antivir Ther; 2006; 11(7):847-55. PubMed ID: 17302247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.